Results 1 to 10 of about 16,601 (119)

Inhibition of amyloid β aggregation by venetoclax: a computational and in vitro experimental approach [PDF]

RSC Advances
The aggregation of amyloid β-protein (Aβ) plays a key role in the pathological progression of Alzheimer's disease (AD). Given the current absence of effective therapeutic strategies, the drug repurposing approach provides novel insights into the ...
Bei-bei Liu, He-cheng Wang, Yi-le He, Liu-jie Zhang, Dong-li Meng, Yun Fu, Ming-yong Wang, Wei Zhang   +7 more
doaj   +2 more sources

Progress in understanding the mechanisms of resistance to BCL-2 inhibitors

Experimental Hematology & Oncology, 2022
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial apoptotic pathway.
Yilan Xu, Haige Ye
doaj   +1 more source

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin

Clinical and Translational Science, 2020
Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetoclax on ...
Ali A. Alhadab, Ahmed Hamed Salem, Kevin J. Freise   +2 more
doaj   +1 more source

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

Pharmaceutics, 2022
Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug
Eric D. Eisenmann, Dominique A. Garrison, Zahra Talebi, Yan Jin, Josie A. Silvaroli, Jin-Gyu Kim, Alex Sparreboom, Michael R. Savona, Alice S. Mims, Sharyn D. Baker   +9 more
doaj   +1 more source

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Haematologica, 2020
Venetoclax is a promising agent in the treatment of acute myeloid leukemia, though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance ...
Xinyu Li, Yongwei Su, Katie Hege, Gerard Madlambayan, Holly Edwards, Tristan Knight, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jay Yang, Regan Miller, Guan Wang, Lijing Zhao, Yue Wang, Hai Lin, Jeffrey W. Taub, Yubin Ge   +17 more
doaj   +1 more source

On the Stability and Degradation Pathways of Venetoclax under Stress Conditions

Pharmaceutics, 2020
Venetoclax is an orally bioavailable, B-cell lymphoma-2 (BCL-2) selective inhibitor, used for the treatment of various types of blood cancers, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Nina Žigart, Martin Črnugelj, Janez Ilaš, Zdenko Časar   +3 more
doaj   +1 more source

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Cell Death and Disease, 2022
Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity.
Damjan Avsec, Marja Škrlj Miklavčič, Tilen Burnik, Maša Kandušer, Maruša Bizjak, Helena Podgornik, Irena Mlinarič-Raščan   +6 more
doaj   +1 more source

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

Cancer Medicine, 2023
Background Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML.
Louise Laloi, Natacha Chaumard Billotey, Pierre‐Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, Florent Puisset, Sarah Bertoli, Marion Boissard Simonet, Kamel Laribi, Dyhia Houyou, Alberto Santagostino, Claire Michel, Gabrielle Roth Guepin, Elodie Guerineau, Reza Tabrizi, Mathilde Hunault, Aurélien Giltat, Eléonore Kaphan, Claude Bulabois, Elodie Cartet, Clément Rocher, Florence Lachenal, Stéphane Morisset, Christian Récher, Arnaud Pigneux, Amine Belhabri, Mauricette Michallet, Anne‐Sophie Michallet   +29 more
doaj   +1 more source

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

Scientific Reports, 2023
Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials ...
Lilly Velentza, Malin Wickström, Per Kogner, Claes Ohlsson, Farasat Zaman, Lars Sävendahl   +5 more
doaj   +1 more source

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

Pathology and Oncology Research, 2023
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation.
Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala   +6 more
doaj   +1 more source